Keyphrases
Age Groups
100%
Randomized Controlled Trial
100%
Treatment Trials
100%
Levetiracetam
100%
Valproate
100%
Fosphenytoin
100%
Status Epilepticus Treatment
100%
Established Status Epilepticus
100%
Older Adults
66%
Safety Outcomes
66%
Benzodiazepines
66%
Efficacy Outcomes
33%
Primary Safety
33%
Response-adaptive
33%
New-onset Refractory Status Epilepticus (NORSE)
33%
Response to Therapy
16%
Treatment Efficacy
16%
Pathophysiology
16%
Neurological Disorders
16%
National Institutes of Health
16%
Hypotension
16%
Life-threatening
16%
Seizure
16%
Ventricular Arrhythmia
16%
Emergency Department
16%
Convulsion
16%
Pharmacist
16%
Underlying Etiologies
16%
Baseline Characteristics
16%
Intention-to-treat
16%
Drug Infusion
16%
Pharmacodynamics
16%
Adequate Dose
16%
Safety Self-efficacy
16%
Secondary Safety
16%
Treatment Allocation
16%
Bayesian Methods
16%
Antiseizure Medication
16%
Endotracheal Intubation
16%
Hospital Emergency Department
16%
Credible Interval
16%
Affect Responses
16%
Second-line Drugs
16%
Generalized Convulsive Seizures
16%
Medicine and Dentistry
Status Epilepticus
100%
Levetiracetam
100%
Fosphenytoin
100%
Randomized Controlled Trial
100%
Sodium Valproate
100%
Benzodiazepine
42%
Adaptive Response
28%
Emergency Department
28%
Drug Therapy
14%
Hypotension
14%
Neurologic Disease
14%
Pathophysiology
14%
Pharmacodynamics
14%
Tracheal Intubation
14%
Apoplexy
14%
Intention-to-Treat Analysis
14%
Tonic-Clonic Seizure
14%
Drug Infusion
14%
Epileptic Seizure
14%
Arrhythmia
14%
Benzodiazepine Derivative
14%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Valproate
100%
Randomized Controlled Trial
100%
Epileptic State
100%
Fosphenytoin Sodium
100%
Levetiracetam
100%
Benzodiazepine
42%
Pharmacodynamics
14%
Hypotension
14%
Neurologic Disease
14%
Heart Arrhythmia
14%
Cerebrovascular Accident
14%
Intubation
14%
Tonic Clonic Seizure
14%
Pathophysiology
14%